Coronavirus Disease (COVID-19) Clinical Trial
— Covid19RehOfficial title:
Would Cardiorespiratory Exercise and Chinese Herbal Medicine Facilitate Rehabilitation Among Post-discharge Patients With COVID-19? Clinical Efficacy and Mechanisms
Rehabilitation interventions can help to address the consequences of COVID-19, which include medical, physical, cognitive, and psychological related problems. The specific aims of this project are to investigate the effects of a 12-week exercise program on pulmonary fibrosis in recovering COVID-19 patients. A further aim will be to examine how Chinese herbal medicines, gut microbiome, and metabolites regulate immune function and possibly autoimmune deficiency in the rehabilitation process.
Status | Recruiting |
Enrollment | 172 |
Est. completion date | June 30, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. aged 18 years and above; 2. a percentage of predicted forced vital capacity (FVC) <90%, and/or a percentage of predicted carbon monoxide diffusing capacity < 90% (King 2014); 3. able to communicate in Cantonese. Exclusion Criteria: 1. having acute exacerbations in the 12-week preceding recruitment patients; 2. having any contraindications for exercise (e.g., physical disability, uncontrolled mental disorders, unstable heart disease, unable to perform muscle strength tests) 3. Female - Pregnant or plan to become pregnant in the next 1 year 4. Unable to communicate in Cantonese or Mandarin 5. Currently participating in other similar rehabilitation programs or research |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Linda Zhong | Kowloon Tong | Kowloon |
Lead Sponsor | Collaborator |
---|---|
Hong Kong Baptist University | Chinese University of Hong Kong, The Hong Kong Polytechnic University, The University of Hong Kong, University of California, San Diego, University of South Wales, Yale University |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Six-Minute Walk Test (6MWT) in Cardiorespiratory Fitness Test | To assess the functional exercise capacity that reflects daily physical activities and to measure the distance the participant is able to walk over six minutes on a hard, flat surface.
Items measured during 6MWT are: Distance Walked (m) Number of Rests |
6 months | |
Primary | Blood Pressure | Blood pressure (Systolic/Diastolic) in mmHg will be measured before & after 6MWT | 6 months | |
Primary | Heart Rate | Heart rate in beats per minute will be measured before & after 6MWT | 6 months | |
Primary | Peripheral oxygen saturation (SpO2) | SpO2 in % will be measured before & after 6MWT | 6 months | |
Primary | Borg Dyspnea Scale | The Borg Category Ratio 10 (CR10) Scale® (Borg Dyspnea Scale), will be used to rate the patients' dyspnea and overall fatigue level. At the beginning and end the end of the 6 MWT. The scale will also be used during Cardiopulmonary Exercise Test (CPET).
Scale: 0=Rest; 0.5=Really Really Easy; 1=Really Easy; 2=Easy; 3=Moderate; 4=Sort of Hard; 5,6=Hard; 7,8,9=Really Hard; 10=Maximal |
6 months | |
Primary | Body composition - Segmental Muscle Mass | Bio-impedance analysis approach will be used to assess patient's segmental muscle mass in percentage (%). | 6 months | |
Primary | Body composition - Body Mass Index (BMI) | A stadiometer will be used to measure stature (in metres) and weight is measured in kg to calculate body mass index (BMI) .
Body Mass Index (BMI): weight (in kilograms) divided by the square of your height (in metres) |
6 months | |
Primary | Body composition - Anatomical Circumferences | Anatomical circumferences - waist (cm) & Hip (cm) will be measured using a steel measuring tape, to calculate the Waist-to-Hip Ratio. | 6 months | |
Primary | FVC (L) in Lung function Test using Spirometry | Forced vital capacity test (FVC) will be measured and used to calculate FEV1/FVC ratio to assess the functional severity and capacity of the patient's lung. | 6 months | |
Primary | FEV1 (L) in Lung function Test using Spirometry | Forced expiratory volume (FEV1) will be measured and used to calculate FEV1 /FVC ratio to assess the functional severity and capacity of the patient's lung. | 6 months | |
Primary | MVV (L/min) in Lung function Test using Spirometry | Maximal Voluntary Ventilation (MVV) measures peak performance of the lungs and respiratory muscles to assess overall pulmonary ventilation. | 6 months | |
Primary | Fractional exhaled Nitric Oxide (FeNO) | Fractional exhaled Nitric Oxide (FeNO), the results will be in parts per billion (ppb) of nitric oxide in patient's breath, will be used to assess inflammatory response to exercise and medicinal intervention. | 6 months | |
Primary | Diffusing capacity of the lungs for carbon monoxide (DLCO) | Diffusing capacity of the lungs for carbon monoxide (DLCO), measured in millilitre/minute/Kilopascal (ml/min/kPa), will be used to evaluate gas diffusion in the lungs. | 6 months | |
Primary | Cardiopulmonary Exercise Test (CPET) - Work Rate(WR) | CPET provides information concerning the level of exercise that the patient can perform without undue stress. The test results will guide the research team regarding exercise prescription for physical rehabilitation methodologies, and provides quantitative evidence of the benefits of a rehabilitation program as well as information on the mechanism(s) involved.
Work Rate(WR), an incremental ergometry exercise test, will be used to assess the cellular, cardiovascular, and ventilatory systems' responses under precise conditions of metabolic stress |
6 months | |
Primary | Cardiopulmonary Exercise Test (CPET) - Breath by Breath Measurements of Minute ventilation (VE) | Breath by breath measurements of minute ventilation (VE) in L/min will be measured and used to calculate ventilatory efficiency - VE/VCO2 and VE/VO2, ventilatory equivalents for carbon dioxide and oxygen. | 6 months | |
Primary | Cardiopulmonary Exercise Test (CPET) - CO2 output (VCO2) | CO2 output (VCO2) in L/min, will be measured and used to calculate ventilatory efficiency - VE/VCO2, ventilatory equivalents for carbon dioxide. | 6 months | |
Primary | Cardiopulmonary Exercise Test (CPET) - O2 uptake (VO2) | O2 uptake (VO2) in L/min, will be measured and used to calculate ventilatory efficiency - VE/VO2, ventilatory equivalents for oxygen. | 6 months | |
Primary | Change in Chinese Medicine (CM) Diagnostic Pattern & Clinical Characteristics using CM Syndrome Differentiation Assessment | The changes in participants' health as characterized by CM diagnostic pattern & clinical characteristics using CM Syndrome Differentiation according to the Guidelines for Chinese Medicine New Drug Clinical Study (China Medical Science Press, 2002) will be assessed. | Change from baseline the CM Diagnostic Pattern & Clinical Characteristics at 6 months | |
Primary | Change in Body Constitution Scores using Body Constitution Questionnaires Assessment | The changes in participants' health as characterized by body constitution scores using the Body Constitution Questionnaires for the nine specific types of body constitutions will be assessed on each visit during the treatment and follow up period. | Change from baseline the Body Constitution at 6 months | |
Secondary | Blood Biochemistry Tests - Serum Levels of Insulin (pmol/l) | Venous blood will be drawn & after coagulation at room temperature for 30 minutes, the samples will be centrifuged at 3000 rpm for 20 minutes. Serum as supernatant will be extracted & stored at -80°C until assay. Serum levels of insulin will be assessed by a commercially available Enzyme-linked immunosorbent Assay (ELISA) kit (Merck). | 6 months | |
Secondary | Blood Biochemistry Tests - Prothrombin Time (seconds) | The Prothrombin time test will be used to measure blood coagulation. Venous blood will be collected by venepuncture in a tube with sodium citrate. Plasma will be isolated after centrifugation at 1000rpm for 30 min, 4°C. Thromboplastin will be added into the plasma and kept at 37°C for two minutes. Calcium chloride will be added to the mixture, and the plasma is allowed to coagulate. The time needed for the coagulation will be recorded as the Prothrombin Time. | 6 months | |
Secondary | Quality of Life - Personal Wellbeing Index - Chinese Version (Adult) | Quality of life (QoL) will be measured using the Personal Well-being Index-Chinese Version (PWI-C). It is a subjective QoL measure with questionnaires that have been translated and validated.
Questions included are: How satisfied are you with…?" your standard of living ? your health ? what you are achieving in life ? your personal relationships ? how safe you feel ? feeling part of your community ? your future security ? Answers are measured using scale from zero to 10 (0...1…2...3...4…5...6...7...8...9…10). Zero means feel no satisfaction at all; 10 means feel completely satisfied. |
6 months | |
Secondary | Other mental health-related measures - Depression Anxiety Stress Scale (DASS-21) | Anxiety and stress will be measured using the Chinese version of the Depression Anxiety Stress Scale (DASS-21). The scale will discriminate between the negative emotional syndromes of depression, anxiety, and stress in Chinese populations. Only the subscales of anxiety and stress will be used.
The anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect. The stress scale is sensitive to levels of chronic nonspecific arousal. It assesses difficulty relaxing, nervous arousal, and being easily upset/agitated, irritable/over-reactive & impatient. The rating scale is as follows: 0=Did not apply to me at all Applied to me to some degree, or some of the time Applied to me to a considerable degree or a good part of time Applied to me very much or most of the time Scores are calculated by summing the scores for the relevant items. Higher scores indicate greater degrees of anxiety and stress. |
6 months | |
Secondary | Other mental health-related measures - Revised UCLA Loneliness Scale (R-UCLA) | Loneliness will be measured using the Revised UCLA Loneliness Scale (R-UCLA). It consists of 20 items and participants are to indicate how often they feel the way described by placing a check in the space provided, using the following scale:
Never Rarely Sometimes Often Score scale for item 1,5,6,9,10,15,16,19,20 are reversed, and score for each item then summed together. Higher scores indicate greater degrees of loneliness. |
6 months | |
Secondary | Other mental health-related measures - General Health Questionnaire (GHQ) | General mental health will be measured using the General Health Questionnaire (GHQ), which is commonly used to screen minor psychiatric symptoms (Hu 2007).
It consists of 12 items, beginning by asking "Have you recently…", each assessing the severity of a mental problem over the past few weeks using a 4-point scale of: (always) 0...1…2…3 (never). The score was used to generate a total score ranging from 0 to 36, with higher scores indicating worse conditions. |
6 months | |
Secondary | Gut microbiome Test | Patient is to self-sample morning first feces & immediately freeze it in a home freezer (-20?) & transport to facilities in a provided freezer pack stored at -80?. Total DNA of 200 mg fecal samples will be extracted & purified. The DNA concentration & size distribution will be estimated by a Nano drop instrument & agarose gel electrophoresis respectively. The DNA one paired-end (PE) library will be prepared using a DNA high-throughput (HT) Sample Prep Kit, & whole-genome shotgun sequencing of samples will be carried out by the Illumina platform. The high quality sequences will be mapped with the published gene catalog of reference genes in the human gut microbiome (Li 2014). Taxonomic assignment of the predicted genes and Kyoto Encyclopedia of Genes & Genomes (KEGG) analysis will be performed as described (Feng 2015). Relative abundances of phyla, genera, species, & Kegg Orthology (KOs) will be calculated from the relative abundances of the respective genes. | 6 months | |
Secondary | Metabolomics-related Measurement of Depression - Metabolomics Analysis | Metabolomics analysis of selected neurotransmitters as potential markers of depression: Ultra-performance liquid chromatography triple quadrupole mass spectrometry will be used to quantitatively measure the metabolites selected (neurotransmitters) as potential markers of depression. Briefly, an aliquot of 40 µl of urine or plasma will be spiked with 10 µL of internal standard (L-4-chlorophenylalanine in water, 30 µg/mL), and extracted with 200 µL of acetonitrile and methanol (9:1, v/v). The mixture will be vortexed and centrifuged. After centrifugation, the supernatant will be transferred to the sampling vials and subject to analysis. The raw data generated will be processed using the Target Lynx Applications Manager Version 4.1 (Waters Corp., Milford, MA) for targeted metabolite annotation and to obtain calibration equations and the concentration of each metabolite in the samples Metabolomics analysis | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04583982 -
ImmuneSense™ COVID-19 Study
|
||
Completed |
NCT04609774 -
Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019
|
||
Terminated |
NCT04569786 -
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
|
Phase 1 | |
Completed |
NCT04575597 -
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
|
Phase 2/Phase 3 | |
Terminated |
NCT04575584 -
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04885361 -
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT04360122 -
Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19
|
Phase 3 | |
Completed |
NCT05119855 -
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
|
Phase 3 | |
Completed |
NCT04558307 -
Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations
|
||
Recruiting |
NCT04584606 -
Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients
|
||
Completed |
NCT04677660 -
A Study of TAK-919 in Healthy Japanese Adults (COVID-19)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04280588 -
Fingolimod in COVID-19
|
Phase 2 | |
Completed |
NCT04941144 -
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
|
||
Terminated |
NCT04498247 -
A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)
|
Phase 1/Phase 2 | |
Completed |
NCT04939428 -
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
|
Phase 3 | |
Withdrawn |
NCT04892888 -
Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms
|
||
Completed |
NCT04348214 -
Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals
|
||
Not yet recruiting |
NCT04350931 -
Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19
|
Phase 3 | |
Not yet recruiting |
NCT04346043 -
To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database
|
||
Not yet recruiting |
NCT04348877 -
Plasma Rich Antibodies From Recovered Patients From COVID19
|
N/A |